Glycolysis in cancer: A potential target for therapy
Glycolysis in cancer: A potential target for therapy
复制标题
DOI：
10.1016/j.biocel.2007.03.021
复制
发表时间：
2007-01-01
影响因子：
4
通讯作者：
Gillies, Robert J.
中科院分区：
文献类型：
--
作者：
Gatenby, Robert A.;Gillies, Robert J.
使用Fluoro deOXY-D-葡萄糖正电子发射断层扫描（FdG PET）对原发性和转移性癌症进行的临床成像已清楚地证明，与正常组织相比，葡萄糖通量增加是人类恶性肿瘤的常见特征（Gambhir，2002）。这是葡萄糖代谢向效率较低的糖酵解途径转变的结果，以响应许多癌症表型中的局部缺氧和有氧糖酵解的演变。这种独特的代谢特征为癌症治疗和预防提供了一个诱人的目标。在这里，我们总结了正在调查的治疗策略，利用或中断肿瘤糖酵解代谢。虽然许多方法正在研究中，但没有一种方法足够成功，可以保证广泛的临床应用。我们指出，可能导致糖酵解上调的肿瘤细胞的环境异质性和进化能力也可以促进适应性策略，从而对旨在抑制葡萄糖代谢的治疗产生抗性。(c)2007爱思唯尔有限公司保留所有权利。
Clinical imaging of primary and metastatic cancers with Fluoro deOXY-D-Glucose Positron Emission Tomography (FdG PET) has clearly demonstrated that increased glucose flux compared to normal tissue is a common trait of human malignancies (Gambhir, 2002) This is a consequence of a shift of glucose metabolism to less efficient glycolytic pathways in response to regional hypoxia and evolution of aerobic glycolysis in many cancer phenotypes. This distinctive metabolic profile presents an inviting target for cancer treatment and prevention. Here, we summarize the therapeutic strategies under investigation to exploit or interrupt tumor glycolytic mefabolism. Although a number of approaches are under investigation, none has been sufficiently successful to warrant widespread clinical application. We point out that the environmental heterogeneity and evolutionary capacity of tumor cells that likely led to development of upregulated glycolysis could also promote adaptive strategies that confer resistance to therapies designed to inhibit glucose metabolism. (c) 2007 Elsevier Ltd. All rights reserved.